Biotech Press Releases

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

First Commercial Deployment of FDA-Cleared AI-Guided TMS Navigation System, Expanded FDA Pathway for NRX-101, and Growing Commercial Infrastructure Highlight Accelerating Momentum for NRx Pharmaceuticals (N A S D A Q: NRXP)

Q2 update reinforces the central NRXP investment thesis: preservative-free ketamine is moving toward commercialization while NRX-101, DARPA funding, HOPE Therapeutics and a stronger balance sheet create multiple potential catalysts.

First-cycle FDA review delivers one of the strongest signals yet that NRx's preservative-free ketamine opportunity may be entering its final stretch, while the company's broader neuropsychiatric pipeline continues to gain momentum.

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

Industry Leaders Identify Operational Excellence, Revenue Leadership, and Strategic Collaboration as the Future of Scalable Enterprise

First Commercial Deployment of FDA-Cleared AI-Guided TMS Navigation System, Expanded FDA Pathway for NRX-101, and Growing Commercial Infrastructure Highlight Accelerating Momentum for NRx Pharmaceuticals (N A S D A Q: NRXP)

Cosmos Health Inc. (N A S D A Q: COSM): 18 Series Nutraceutical Expansion, Record Q1 Results, EIB Financing Initiative, AI-Powered Drug Development, And Strong Long-Term Financial Guidance Position Cosmos Health For Potential Multi-Year Expansion

Cosmos Health Inc. (N A S D A Q: COSM): Veterinary Expansion, Proprietary Healthcare Brands, AI-Powered Drug Development, Telehealth Growth, and Strong Financial Guidance Position Cosmos Health for Potential Multi-Year Expansion

Expanding HOPE Therapeutics Network Positions NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP for Potential Breakout 2026 Growth

NRx Pharmaceuticals, Inc.Improved Financial Position, Commercial Ketamine Manufacturing, FDA Progress, and Expanding Neuroplastic Therapy Infrastructure Position $NRXP for a Potential Breakout Phase

Commercial-Ready Ketamine Production, FDA Alignment, and Expanding AI Neurotherapy Platform Position $NRXP at the Center of a Multi-Billion-Dollar Mental Health Transformation

NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP: Dual FDA Pathways, and an Expanding AI-Driven Treatment Ecosystem Position NRXP at the Forefront of a Multi-Billion-Dollar Mental Health Transformation

Proprietary Stem Cell Platform Meets Institutional-Grade AI Infrastructure—Positioning $KALA at the Center of a Massive, Underserved $167B R&D Opportunity

Breakthrough Regulatory Alignment Now Meets Cutting-Edge Robotic Brain Therapy—Positioning $NRXP at the Intersection of Pharma, AI, and National Defense

Positive Phase II Results, Ongoing Phase III Trial, and Cash Runway Into Late-2027 Positions Cardiol Therapeutics Inc. (N A S D A Q: CRDL) $CRDL for Transformational Growth

Secure, on-premises AI infrastructure, recurring revenue model, and entry into a $167B+ R&D ecosystem position $KALA at the forefront of the agentic AI healthcare revolution

NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP Has a One-Day Depression Treatment, AI Monitoring Breakthrough, and Potential 2026 Drug Approval Put $NRXP in a Category of Its Own

Philanthropic venture fund supports next generation of startups to expand opportunity and economic growth for future generations

Accelerating scalable AI infrastructure, secures up to $9.75M financing, and advances FDA-registered diagnostic technology alongside next-generation generative AI platforms $ALBT

87% Clinical Response From Non-Invasive Neuroplastic Therapy Positions $NRXP at the Forefront of Next-Generation Mental Health Treatment. NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)

TAEUS® Technology Delivers MRI-Level Liver Fat Measurement at the Point of Care for Disease Affecting 30% of Adults Worldwide: $NDRA

KALA BIO, Inc. (N A S D A Q: KALA) $KALA Targets Massive AI Opportunity in Biotech with Secure On-Premises Infrastructure Platform

Green Seal-Certified. Hospital-Grade Disinfection Meets Explosive Omni-Channel Growth Strategy Including pet-care, and biosafety sectors.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP: FDA Alignment, 70,000-Patient Real-World Data, and a Debt-Free Balance Sheet Position NRXP for Transformational 2026 Catalysts

Company focuses on compliant, research-use-only biotech compounds for laboratory clients

Collaboration Carried Out With Support from Brain Research UK

Biobase, a healthcare data infrastructure company pioneering the first agentic operating system for clinical data, received a strategic investment from BJC Health that will position BJC as a center of excellence for deploying next-generation AI solutions.

Bridging the orbital care gap: As NASA reassesses ISS medical protocols, Diopter Labs reveals a shelf-stable "clinic-in-a-lens" built to stop space-flight emergencies before they require evacuation.

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP has Entered into a Joint Offering with neurocare Group for Neuroplastic Therapy Targeting Depression, PTSD and Other Mental Health Afflictions

BullFrog AI Holdings, Inc. (N A S D A Q: BFRG) $BFRG Published Whitepaper Titled "AI in Bioinformatics: Turning Complex Data into Actionable Insights with BullFrog Data Networks®"

VSee Health, Inc. (N A S D A Q: VSEE) $VSEE Reported Q3 Revenues Reach $3.98 Million, Up 19% Year-Over-Year with Clients Including NASA, U.S. Department of Health and Human Services, McKesson, DaVita and The Nation of Qatar

NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) NRXP Also Reports Its Superior Preservative-Free IV Ketamine Now Submitted for FDA Abbreviated New Drug Application